Does serial administration of gadolinium-based contrast agents affect patient neurological and neuropsychological status? Fourteen-year follow-up of patients receiving more than fifty contrast administrations.
作者信息
Vymazal Josef, Krámská Lenka, Brožová Hana, Růžička Evžen, Rulseh Aaron M
机构信息
Department of Radiology, Na Homolce Hospital, Prague, Czech Republic.
Department of Neurology, Clinical Psychology, Na Homolce Hospital, Prague, Czech Republic.
出版信息
J Magn Reson Imaging. 2020 Jun;51(6):1912-1913. doi: 10.1002/jmri.26948. Epub 2019 Oct 30.
Abstract
摘要
相似文献
1
Does serial administration of gadolinium-based contrast agents affect patient neurological and neuropsychological status? Fourteen-year follow-up of patients receiving more than fifty contrast administrations.
J Magn Reson Imaging. 2020 Jun;51(6):1912-1913. doi: 10.1002/jmri.26948. Epub 2019 Oct 30.
2
Effects of serial macrocyclic-based contrast materials gadoterate meglumine and gadobutrol administrations on gadolinium-related dentate nuclei signal increases in unenhanced T1-weighted brain: a retrospective study in 158 multiple sclerosis (MS) patients.
Radiol Med. 2018 Feb;123(2):125-134. doi: 10.1007/s11547-017-0816-9. Epub 2017 Sep 27.
3
Evaluation of Gadolinium Retention After Serial Administrations of a Macrocyclic Gadolinium-Based Contrast Agent (Gadobutrol): A Single-Institution Experience With 189 Patients.
Invest Radiol. 2018 Jan;53(1):20-25. doi: 10.1097/RLI.0000000000000404.
4
Commentary on T1-Weighted Hypersignal in the Deep Cerebellar Nuclei After Repeated Administrations of Gadolinium-Based Contrast Agents in Healthy Rats: Difference Between Linear and Macrocyclic Agents.
Invest Radiol. 2015 Aug;50(8):481-2. doi: 10.1097/RLI.0000000000000182.
5
Intraindividual Analysis of Signal Intensity Changes in the Dentate Nucleus After Consecutive Serial Applications of Linear and Macrocyclic Gadolinium-Based Contrast Agents.
Invest Radiol. 2016 Nov;51(11):683-690. doi: 10.1097/RLI.0000000000000308.
6
Progressive T1 Shortening of the Dentate Nucleus in Patients With Multiple Sclerosis: Result of Multiple Administrations of Linear Gadolinium Contrast Agents Versus Intrinsic Disease.
AJR Am J Roentgenol. 2018 Nov;211(5):1099-1105. doi: 10.2214/AJR.17.19155. Epub 2018 Aug 30.
7
Signal intensity at unenhanced T1-weighted magnetic resonance in the globus pallidus and dentate nucleus after serial administrations of a macrocyclic gadolinium-based contrast agent in children.
Pediatr Radiol. 2017 Sep;47(10):1345-1352. doi: 10.1007/s00247-017-3874-1. Epub 2017 May 19.
8
Development of High Signal Intensity within the Globus Pallidus and Dentate Nucleus following Multiple Administrations of Gadobenate Dimeglumine.
AJNR Am J Neuroradiol. 2018 Mar;39(3):415-420. doi: 10.3174/ajnr.A5510. Epub 2018 Jan 18.
9
High Signal Intensity in the Dentate Nucleus and Globus Pallidus on Unenhanced T1-Weighted MR Images: Comparison between Gadobutrol and Linear Gadolinium-Based Contrast Agents.
AJNR Am J Neuroradiol. 2018 Mar;39(3):421-426. doi: 10.3174/ajnr.A5538. Epub 2018 Feb 1.
10
Comparison of Unenhanced T1-Weighted Signal Intensities Within the Dentate Nucleus and the Globus Pallidus After Serial Applications of Gadopentetate Dimeglumine Versus Gadobutrol in a Pediatric Population.
Invest Radiol. 2018 Feb;53(2):119-127. doi: 10.1097/RLI.0000000000000419.
引用本文的文献
1
MRI contrast agents and retention in the brain: review of contemporary knowledge and recommendations to the future.
Insights Imaging. 2024 Jul 25;15(1):179. doi: 10.1186/s13244-024-01763-z.
2
Ten years of gadolinium retention and deposition: ESMRMB-GREC looks backward and forward.
Eur Radiol. 2024 Jan;34(1):600-611. doi: 10.1007/s00330-023-10281-3. Epub 2023 Oct 7.
3
Assessment of Microvascular Disease in Heart and Brain by MRI: Application in Heart Failure with Preserved Ejection Fraction and Cerebral Small Vessel Disease.
Medicina (Kaunas). 2023 Sep 4;59(9):1596. doi: 10.3390/medicina59091596.
4
MR Imaging Signs of Gadolinium Retention Are Not Associated with Long-Term Motor and Cognitive Outcomes in Multiple Sclerosis.
AJNR Am J Neuroradiol. 2023 Apr;44(4):396-402. doi: 10.3174/ajnr.A7807. Epub 2023 Mar 2.
5
Safety of Gadolinium-Based Contrast Agents in Patients with Stage 4 and 5 Chronic Kidney Disease: a Radiologist's Perspective.
Kidney360. 2020 Jan 9;1(2):123-126. doi: 10.34067/KID.0000502019. eCollection 2020 Feb 27.
6
The TRUTH confirmed: validation of an intraindividual comparison of gadobutrol and gadoteridol for imaging of glioblastoma using quantitative enhancement analysis.
Eur Radiol Exp. 2021 Oct 12;5(1):46. doi: 10.1186/s41747-021-00240-2.
7
Dose-Lowering in Contrast-Enhanced MRI of the Central Nervous System: A Retrospective, Parallel-Group Comparison Using Gadobenate Dimeglumine.
J Magn Reson Imaging. 2021 Nov;54(5):1660-1675. doi: 10.1002/jmri.27731. Epub 2021 May 20.
8
Safety and diagnostic efficacy of gadoteridol for magnetic resonance imaging of the brain and spine in children 2 years of age and younger.
Pediatr Radiol. 2021 Sep;51(10):1895-1906. doi: 10.1007/s00247-021-05069-w. Epub 2021 May 5.
9
Comprehensive phenotyping revealed transient startle response reduction and histopathological gadolinium localization to perineuronal nets after gadodiamide administration in rats.
Sci Rep. 2020 Dec 28;10(1):22385. doi: 10.1038/s41598-020-79374-z.
10
Gadolinium Deposition Safety: Seeking the Patient's Perspective.
AJNR Am J Neuroradiol. 2020 Jun;41(6):944-946. doi: 10.3174/ajnr.A6586. Epub 2020 May 7.
本文引用的文献
1
MRI features suggestive of gadolinium retention do not correlate with Expanded Disability Status Scale worsening in Multiple Sclerosis.
Neuroradiology. 2019 Feb;61(2):155-162. doi: 10.1007/s00234-018-02150-4. Epub 2019 Jan 8.
2
Retention of Gadolinium-Based Contrast Agents in Multiple Sclerosis: Retrospective Analysis of an 18-Year Longitudinal Study.
AJNR Am J Neuroradiol. 2017 Jul;38(7):1311-1316. doi: 10.3174/ajnr.A5211. Epub 2017 May 11.
3
The Cognitive Role of the Globus Pallidus interna; Insights from Disease States.
Exp Brain Res. 2017 May;235(5):1455-1465. doi: 10.1007/s00221-017-4905-8. Epub 2017 Feb 28.
4
Association Between Gadolinium Contrast Exposure and the Risk of Parkinsonism.
JAMA. 2016 Jul 5;316(1):96-8. doi: 10.1001/jama.2016.8096.
5
Gadolinium-based Contrast Agent Accumulates in the Brain Even in Subjects without Severe Renal Dysfunction: Evaluation of Autopsy Brain Specimens with Inductively Coupled Plasma Mass Spectroscopy.
Radiology. 2015 Jul;276(1):228-32. doi: 10.1148/radiol.2015142690. Epub 2015 May 5.
6
Glioblastoma and other malignant gliomas: a clinical review.
JAMA. 2013 Nov 6;310(17):1842-50. doi: 10.1001/jama.2013.280319.
7
Long-term survival of patients suffering from glioblastoma multiforme treated with tumor-treating fields.
World J Surg Oncol. 2012 Oct 24;10:220. doi: 10.1186/1477-7819-10-220.
8
Disease severity and progression in progressive supranuclear palsy and multiple system atrophy: validation of the NNIPPS--Parkinson Plus Scale.
PLoS One. 2011;6(8):e22293. doi: 10.1371/journal.pone.0022293. Epub 2011 Aug 4.
Zotero 插件